Discovery of pyrrolidine-based β-secretase inhibitors: Lead advancement through conformational design for maintenance of ligand binding efficiency
Graphical abstract
We have developed a novel series of pyrrolidine derived BACE-1 inhibitors. The potency of the weak initial lead structure was enhanced using library-based SAR methods. The series was then further advanced by rational design while maintaining a minimal ligand binding efficiency threshold. Ultimately, the co-crystal structure was obtained revealing that these inhibitors interacted with the enzyme in a unique fashion and allowed for potent binding in a nontraditional fashion. In all, the potency of the series was enhanced by 4 orders of magnitude from the HTS lead with concomitant increases in physical properties needed for series advancement. The progression of these developments in a systematic fashion is described.
References and notes (12)
- et al.
J. Alz. Res.
(2005) Drug Devel. Res.
(2009)- et al.
J. Med. Chem.
(2008)et al.J. Med. Chem.
(2007)et al.J. Med. Chem.
(2006)
There are more references available in the full text version of this article.
Cited by (0)
Copyright © 2011 Elsevier Ltd. All rights reserved.